Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Site-directed delivery of nitric oxide to cancers.

Sharma K, Chakrapani H.

Nitric Oxide. 2014 Dec 1;43:8-16. doi: 10.1016/j.niox.2014.07.005. Review.

PMID:
25124221
2.

Nitroreductase-activated nitric oxide (NO) prodrugs.

Sharma K, Sengupta K, Chakrapani H.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5964-7. doi: 10.1016/j.bmcl.2013.08.066.

PMID:
24050886
4.

Enzyme-catalyzed activation of anticancer prodrugs.

Rooseboom M, Commandeur JN, Vermeulen NP.

Pharmacol Rev. 2004 Mar;56(1):53-102. Review.

5.

Nitric oxide-donating materials and their potential in pharmacological applications for site-specific nitric oxide delivery.

Eroy-Reveles AA, Mascharak PK.

Future Med Chem. 2009 Nov;1(8):1497-507. doi: 10.4155/fmc.09.111. Review.

PMID:
21426062
6.

Colloidal gold modified with a genetically engineered nitroreductase: toward a novel enzyme delivery system for cancer prodrug therapy.

Gwenin VV, Gwenin CD, Kalaji M.

Langmuir. 2011 Dec 6;27(23):14300-7. doi: 10.1021/la202951p.

PMID:
22014024
7.

Targeted enzyme prodrug therapies.

Schellmann N, Deckert PM, Bachran D, Fuchs H, Bachran C.

Mini Rev Med Chem. 2010 Sep;10(10):887-904. Review.

PMID:
20560876
8.

JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.

Laschak M, Spindler KD, Schrader AJ, Hessenauer A, Streicher W, Schrader M, Cronauer MV.

BMC Cancer. 2012 Mar 30;12:130. doi: 10.1186/1471-2407-12-130.

9.
10.

Strategies for enzyme/prodrug cancer therapy.

Xu G, McLeod HL.

Clin Cancer Res. 2001 Nov;7(11):3314-24. Review.

11.

INDQ/NO, a bioreductively activated nitric oxide prodrug.

Sharma K, Iyer A, Sengupta K, Chakrapani H.

Org Lett. 2013 Jun 7;15(11):2636-9. doi: 10.1021/ol400884v.

PMID:
23659457
12.

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.

Williams EM, Little RF, Mowday AM, Rich MH, Chan-Hyams JV, Copp JN, Smaill JB, Patterson AV, Ackerley DF.

Biochem J. 2015 Oct 15;471(2):131-53. doi: 10.1042/BJ20150650. Review.

PMID:
26431849
13.

Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.

HariKrishna D, Rao AR, Krishna DR.

Drug News Perspect. 2003 Jun;16(5):309-18. Review.

PMID:
12942162
14.

The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.

Maciag AE, Saavedra JE, Chakrapani H.

Anticancer Agents Med Chem. 2009 Sep;9(7):798-803. Review.

PMID:
19538173
15.

Nitric oxide--a novel therapeutic for cancer.

Coulter JA, McCarthy HO, Xiang J, Roedl W, Wagner E, Robson T, Hirst DG.

Nitric Oxide. 2008 Sep;19(2):192-8. doi: 10.1016/j.niox.2008.04.023. Review.

PMID:
18485922
16.

Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues.

Nichols SP, Storm WL, Koh A, Schoenfisch MH.

Adv Drug Deliv Rev. 2012 Sep;64(12):1177-88. doi: 10.1016/j.addr.2012.03.002. Review.

17.

Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.

Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S.

Anticancer Drug Des. 1999 Dec;14(6):473-86. Review.

PMID:
10834269
18.

Targeted prodrug approaches for hormone refractory prostate cancer.

Aloysius H, Hu L.

Med Res Rev. 2015 May;35(3):554-85. doi: 10.1002/med.21333. Review.

PMID:
25529338
19.

Targeted prodrug design to optimize drug delivery.

Han HK, Amidon GL.

AAPS PharmSci. 2000;2(1):E6. Review.

20.

Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.

Smith GK, Banks S, Blumenkopf TA, Cory M, Humphreys J, Laethem RM, Miller J, Moxham CP, Mullin R, Ray PH, Walton LM, Wolfe LA 3rd.

J Biol Chem. 1997 Jun 20;272(25):15804-16.

Supplemental Content

Support Center